Cogent Biosciences (COGT) Price & Analysis

Compare

563 Followers

COGT Stock Chart & Stats

Day’s Range― - ―

52-Week Range$3.72 - $12.61

Previous CloseN/A

Volume181.15K

Average Volume (3M)1.91M

Market Cap

$808.38M

Enterprise Value$558.79M

Total Cash (Recent Filing)$245.66M

Total Debt (Recent Filing)$17.09M

Price to Earnings (P/E)―

Beta0.99

Next Earnings

Aug 12, 2025

EPS Estimate

-0.58

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.64

Shares Outstanding113,856,450

10 Day Avg. Volume2,284,981

30 Day Avg. Volume1,913,028

Financial Highlights & Ratios

PEG Ratio-0.23

Price to Book (P/B)2.66

Price to Sales (P/S)0.00

P/FCF Ratio-5.41

Enterprise Value/Market Cap0.69

Enterprise Value/Revenue50.00

Enterprise Value/Gross Profit-517.40

Enterprise Value/Ebitda-0.53

Forecast

1Y Price Target

$16.57

Price Target Upside133.38% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

Cogent Biosciences News

PremiumThe Fly

Cogent Biosciences secures up to $400M in non-dilutive financing

18d ago

COGT

PremiumCompany Announcements

Cogent Biosciences Secures $400M Debt Financing Facility

18d ago

COGT

PremiumCompany Announcements

Cogent Biosciences Approves Officer Exculpation Amendment

24d ago

COGT

PremiumThe Fly

Cogent Biosciences price target raised to $25 from $21 at JPMorgan

1M ago

COGT

PremiumRatings

Cogent Biosciences: Strong Financial Management and Promising Clinical Trials Support Buy Rating

1M ago

COGT

PremiumThe Fly

Cogent Biosciences price target lowered to $12 from $14 at H.C. Wainwright

1M ago

COGT

PremiumRatings

Cogent Biosciences: Promising Pipeline and Market Opportunities Drive Buy Rating

2M ago

COGT

PremiumThe Fly

Cogent Biosciences price target lowered to $7 from $8 at Baird

2M ago

COGT

See All COGT News

See All News >

Bulls Say, Bears Say

Bulls Say

Clinical Trial ProgressCogent Biosciences reported that all programs and timelines are on track for pivotal readouts for all three indications for lead asset bezuclastinib.

Financial FlexibilityCogent Biosciences has secured a credit facility with SLR Capital Partners, unlocking up to $400M worth of non-dilutive capital for working capital and general business purposes.

Market OpportunityNon-advanced systemic mastocytosis is viewed as a $2 billion plus US annual market opportunity.

Bears Say

Investor SkepticismCogent Biosciences faces a high short interest, which could indicate skepticism among investors regarding its stock performance.

Safety ConcernsInvestors are focusing on the liver profile of bezuclastinib following the disclosure of 3 cases of Grade 3 AST/ALT elevations in indolent systemic mastocytosis.

Safety Profile ChallengesBezu's safety profile in Non-AdvSM could remain a headwind as COGT reports data from a larger cohort in SUMMIT Part 2.

Financials

Income Statement >

Options Prices

Detailed Option Prices >

Ownership Overview

11.61% Insiders

20.42% Mutual Funds

0.68% Other Institutional Investors

55.25% Public Companies and Individual Investors

Detailed Ownership Overview >

COGT FAQ

What was Cogent Biosciences’s price range in the past 12 months?

Cogent Biosciences lowest stock price was $3.72 and its highest was $12.61 in the past 12 months.

What is Cogent Biosciences’s market cap?

Cogent Biosciences’s market cap is $808.38M.

When is Cogent Biosciences’s upcoming earnings report date?

Cogent Biosciences’s upcoming earnings report date is Aug 12, 2025 which is in 44 days.

How were Cogent Biosciences’s earnings last quarter?

Cogent Biosciences released its earnings results on May 06, 2025. The company reported -$0.635 earnings per share for the quarter, missing the consensus estimate of -$0.593 by -$0.042.

Is Cogent Biosciences overvalued?

According to Wall Street analysts Cogent Biosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Cogent Biosciences pay dividends?

Cogent Biosciences does not currently pay dividends.

What is Cogent Biosciences’s EPS estimate?

Cogent Biosciences’s EPS estimate is -0.58.

How many shares outstanding does Cogent Biosciences have?

Cogent Biosciences has 113,856,450 shares outstanding.

What happened to Cogent Biosciences’s price movement after its last earnings report?

Cogent Biosciences reported an EPS of -$0.635 in its last earnings report, missing expectations of -$0.593. Following the earnings report the stock price went down -15.619%.

Which hedge fund is a major shareholder of Cogent Biosciences?

Currently, no hedge funds are holding shares in COGT

Cogent Biosciences Stock Smart Score

Neutral

Fundamentals

Return on Equity

-84.04%

Trailing 12-Months

Asset Growth

-40.39%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Cogent Biosciences

Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies to treat genetically driven diseases. The company operates primarily in the biopharmaceutical sector and is dedicated to advancing its core product pipeline, which includes experimental therapies for specific genetic mutations linked to rare disorders and cancers. Cogent Biosciences aims to address unmet medical needs through targeted treatment options, leveraging its expertise in genetic and molecular biology.

COGT Stock 12 Month Forecast

Average Price Target

$16.57

▲(133.38%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","15":"$15","26":"$26","9.5":"$9.5","20.5":"$20.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16.57,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$16.57</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,9.5,15,20.5,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.61,7.101538461538462,8.593076923076923,10.084615384615386,11.576153846153847,13.067692307692308,14.55923076923077,16.05076923076923,17.54230769230769,19.033846153846152,20.525384615384613,22.016923076923074,23.50846153846154,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.61,6.453076923076924,7.296153846153847,8.13923076923077,8.982307692307693,9.825384615384616,10.668461538461539,11.511538461538462,12.354615384615386,13.197692307692309,14.040769230769232,14.883846153846154,15.726923076923079,{"y":16.57,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.61,5.716923076923077,5.823846153846154,5.930769230769231,6.037692307692308,6.144615384615385,6.251538461538462,6.358461538461539,6.4653846153846155,6.572307692307692,6.679230769230769,6.786153846153846,6.893076923076923,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.9,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.93,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.01,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.36,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.74,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.75,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.72,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.47,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.8,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.31,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.53,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.63,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.61,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >